Sector Chart Allergan plc

Equities

Delayed Nyse Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

03-05	Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	CI
2023	Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes